What is IVVD's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.21B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for IVVD?

P/E (TTM) is n/a and 52-week range is $0.53 to $3.07 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s IVVD figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for IVVD?

The company profile lists revenue (TTM) near $54M, net income (TTM) near $-9.87B, EPS (TTM) near $-0.37 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Invivyd Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in New Haven, Connecticut, US, 294.6M shares outstanding, ISIN US00534A1025 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Invivyd Inc

$IVVD

Health Care · Biotechnology

IR Run Scenarios

$0.72

+2.97%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Invivyd, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is headquartered in New Haven, Connecticut and currently employs 122 full-time employees. The company went IPO on 2021-08-06. The Company’s proprietary INVYMAB platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid, serial generation of new monoclonal antibodies (mAbs) to keep pace with evolving viral threats. The firm delivers antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, such as SARS-CoV-2. Its PEMGARDA (pemivibart) is the Company's first mAb to receive regulatory authorization and is designed to keep pace with SARS-CoV-2 viral evolution. PEMGARDA is used for the pre-exposure prophylaxis (prevention) of COVID-19 in adults and adolescents. Its VYD2311 is optimized for neutralization potency against SARS-CoV-2 lineages such as BA.2.86 and JN.1. The firm also has additional anti-SARS-CoV-2 mAb candidates in discovery and pre-clinical characterization.

Employees

122

Website

invivyd.com/

IPO

2021-08-06

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)